Literature DB >> 26297630

Applicability of the Zwolle risk score for safe early discharge after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction.

António Tralhão1, António Miguel Ferreira2, Sérgio Madeira2, Miguel Borges Santos2, Mariana Castro2, Ingrid Rosário2, Marisa Trabulo2, Carlos Aguiar2, Jorge Ferreira2, Manuel Sousa Almeida2, Miguel Mendes2.   

Abstract

INTRODUCTION AND AIM: The optimal length of stay for patients with uncomplicated ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI) is still undetermined. The Zwolle risk score (ZRS) is a simple tool designed to identify patients who can be safely discharged within 72 hours. The purpose of this study was to assess the applicability and performance of the ZRS in our population.
METHODS: We studied 276 consecutive patients (mean age 62 ± 14 years, 75% male, 20% Killip class >1) admitted over a two-year period for STEMI and treated with PPCI. ZRS, length of stay, 30-day mortality and readmission were obtained for all patients. Low risk was defined as ZRS ≤ 3.
RESULTS: The median ZRS was 3 (interquartile range [IQR] 1-4), with 171 patients (62%) being classified as low risk. Thirty-day mortality was 4.7% (13 patients). Compared to other patients, low-risk patients had shorter length of stay (median 5.0 [IQR 4-7] vs. 7.0 [5-13] days, p<0.001), and lower 30-day mortality (0 vs. 12.4%, p<0.001), yielding a negative predictive value of 100% (95% CI 97.0-100%) for the proposed cutoff. The ZRS showed excellent discriminative power (C-statistic: 0.937, 95% CI 0.906-0.968, p<0.001), and good calibration against the original cohort.
CONCLUSIONS: The ZRS appears to perform well in identifying low-risk STEMI patients who could be safely discharged within 72 hours of admission. Using the ZRS in our population could result in a more rational use of in-patient resources.
Copyright © 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Entities:  

Keywords:  Alta precoce; Early discharge; Enfarte agudo do miocárdio com supradesnivelamento de ST; Intervenção coronária percutânea primária; Primary percutaneous coronary intervention; ST-segment elevation myocardial infarction; Score de Zwolle; Zwolle risk score

Mesh:

Year:  2015        PMID: 26297630     DOI: 10.1016/j.repc.2015.04.006

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  4 in total

1.  Value-Based ST-Segment-Elevation Myocardial Infarction Care Using Risk-Guided Triage and Early Discharge.

Authors:  Joseph E Ebinger; Craig E Strauss; Ross R Garberich; Steven M Bradley; Pam Rush; Ivan J Chavez; Anil K Poulose; Brandon R Porten; Timothy D Henry
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-04

2.  Very Early Discharge of Patients with ST-Segment-Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention.

Authors:  Seyed Kianoosh Hosseini; Behshad Naghshtabrizi; Farzad Emami; Amirhossein Yazdi; Nima Naghshtabrizi; Sara Zebarjadi
Journal:  J Tehran Heart Cent       Date:  2021-07

Review 3.  Management of Acute Coronary Syndromes During the Coronavirus Disease 2019 Pandemic: Deviations from Guidelines and Pragmatic Considerations for Patients and Healthcare Workers.

Authors:  Henry Seligman; Sayan Sen; Sukhjinder Nijjer; Rasha Al-Lamee; Piers Clifford; Amarjit Sethi; Nearchos Hadjiloizou; Raffi Kaprielian; Punit Ramrakha; Michael Bellamy; Masood A Khan; Jaspal Kooner; Rodney A Foale; Ghada Mikhail; Christopher S Baker; Jamil Mayet; Iqbal Malik; Ramzi Khamis; Darrel Francis; Ricardo Petraco
Journal:  Interv Cardiol       Date:  2020-11-24

4.  Zwolle Risk Score for Safety Assessment of Same-day Discharge after Primary Percutaneous Coronary Intervention.

Authors:  Jehangir Ali Shah; Bashir Ahmed Solangi; Mahesh Kumar Batra; Kamran Ahmed Khan; Ghazanfar Ali Shah; Gulzar Ali; Mehwish Zehra; Muhammad Hassan; Muhammad Zubair; Musa Karim
Journal:  J Saudi Heart Assoc       Date:  2021-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.